Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody drug it’s testing against several respiratory diseases. The Waltham, Massachusetts-based biotechnology company sold …